ANDA label proofreading deficiencies still holding up approvals, OGD study finds.
Executive Summary
ANDA LABELING DEFICIENCIES: ONE-THIRD DUE TO PROOFREADING PROBLEMS, according to a 1994 study recently released by FDA. The report by the Office of Generic Drugs Labeling Review Branch contends that "improved proofreading, being familiar with the full range of references in the Code of Federal Regulations, and becoming familiar with the agency preferences will significantly reduce the number of labeling deficiencies cited in `not approvable' letters and greatly facilitate the review process."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth